eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2010
vol. 14
 
Share:
Share:
abstract:
Review paper

Bevacizumab plus irinotecan in treatment of recurrent brain gliomas

Rafał Stec
,
Lubomir Bodnar
,
Marta Smoter
,
Cezary Szczylik

Współczesna Onkologia (2010) vol. 14;4 (253-358)
Online publish date: 2010/09/09
View full text Get citation
 
PlumX metrics:
Malignant gliomas including WHO grade III and grade IV tumours are a rare neoplasm (0.5% to 1% of all cancers). No standard therapy is available in the case of disease recurrence. In this review we assess the available literature evaluating the effect of chemoimmunotherapy based on bevacizumab and irinotecan in patients with recurrent WHO grade III and IV gliomas. Malignant gliomas are highly vascular and often express abundant amounts of vascular endothelial growth factor (VEGF). Neoplastic progression is dependent on angiogenesis, and anti-VEGF therapy has been successful in multiple disease states. Bevacizumab is a humanized monoclonal antibody that binds to and inhibits the activity of VEGF. Bevacizumab combined with irinotecan, an inhibitor of topoisomerase I, with good penetration to the CNS, appears to improve 6-month progression-free survival by 29% to 55%.
Conclusion: Bevacizumab in combination with irinotecan could be an active regimen for patients with recurrent WHO grade III and grade IV gliomas.
keywords:

bevacizumab, irinotecan, gliomas grade III and IV

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.